SciCombinator

Discover the most talked about and latest scientific content & concepts.

Point-of-Care Warfarin Monitoring in the ROCKET AF Trial

OPEN The New England journal of medicine | 4 Feb 2016

MR Patel, AS Hellkamp and KA Fox
Abstract
To the Editor: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), investigators found that rivaroxaban was noninferior to warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation.(1) In December 2014, four years after completion of the trial, the Food and Drug Administration (FDA) issued a recall notice for a medical device correction of the Alere INRatio Monitor System (formally known as the Hemosense INRatio device). The recall correction notice was issued because the FDA-approved and European . . .
Tweets*
53
Facebook likes*
3
Reddit*
0
News coverage*
31
Blogs*
3
SC clicks
0
Concepts
Embolism, Vitamin K, Anticoagulant, Thrombus, Coagulation, Stroke, Atrial fibrillation, Warfarin
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com